Neil Bander

Company: Convergent Therapeutics

Job title: Founder, Chief Scientific Officer

Bio:

Dr. Neil H. Bander is the former Bernard and Josephine Chaus Professor of Urologic Oncology and current Professor Emeritus of Urology at Weill Cornell Medicine. While at Weill Cornell, his group developed the first monoclonal antibodies to prostate-specific membrane antigen (PSMA) that could successfully target prostate cancers in patients. This enabled them to define much of the biology of PSMA and clinically validate PSMA as a target in prostate and other cancers. As a result of Dr. Bander and his team’s pioneering efforts, PSMA has become a target of substantial interest and activity in bio-pharma. 

Dr. Bander is a surgeon-scientist trained in urological oncology and tumor immunology, both at Memorial Sloan Kettering Cancer Center. He has authored approximately 200 peer-reviewed publications, and he is an inventor on approximately 150 US and foreign issued and pending patents. He has served on, and chaired, multiple study sections and grant review panels and received several honors including the FC Valentine Fellowship from the NY Academy of Medicine, the Society of Surgical Oncology James Ewing Research Award, awards from the German and Japanese Urology Societies, the Prostate Cancer Foundation, and the Clark Medal for Surgical Innovation from the Royal College of Surgeons (London). He also serves on several industry Scientific Advisory Boards. 

Seminars:

A Version of ADCs: Antibody Formats Amenable to Improving PK/PD of Radiopharmaceuticals 1:45 pm

Discussing differences in the mechanisms of action for an ADC versus radiopharmaceutical Exploring different antibody fragments to target and deliver radioactivity to the tumor and generate a good half-life locally Insights into novel click cleavable ADCs for delivery of radiotherapeuticsRead more

day: Day One - PM

The Radiopharmaceutical Fork in the Road: Radioantibodies versus Radioligands 2:30 pm

Does the success of Lutathera and Pluvicto foretell a wave of effective Radioligands Paradoxical advantages/disadvantages of ligands and antibodies Blending Radioantibodies and Radioligands: the ideal Radiopharmaceutical approachRead more

day: Day One - PM